SG11201807012QA - Acid addition salts of piperazine derivatives - Google Patents
Acid addition salts of piperazine derivativesInfo
- Publication number
- SG11201807012QA SG11201807012QA SG11201807012QA SG11201807012QA SG11201807012QA SG 11201807012Q A SG11201807012Q A SG 11201807012QA SG 11201807012Q A SG11201807012Q A SG 11201807012QA SG 11201807012Q A SG11201807012Q A SG 11201807012QA SG 11201807012Q A SG11201807012Q A SG 11201807012QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- co7d
- acid addition
- addition salts
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization M1111101110101011111 HO 1111101110101110M1011100 1111111110111011# 11 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date .......,,,i WO 2017/144637 Al 31 August 2017 (31.08.2017) WIPO I PCT (51) International Patent Classification: (74) Agent: ZEMAN, Steven; Grilnecker Patent- and Recht- CO7D 417/12 (2006.01) A61K 31/497 (2006.01) sanwalte PartG mbB, Leopoldstr. 4, 80802 Miinchen (DE). CO7D 405/12 (2006.01) A61K 31/506 (2006.01) C07D 417/14 (2006.01) A61K 31/5377 (2006.01) (81) Designated States (unless otherwise indicated, for every C07D 405/14 (2006.01) A61P 25/00 (2006.01) kind of national protection available): AE, AG, AL, AM, CO7D 513/04 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, PCT/EP2017/054278 HN, KP, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 24 February 2017 (24.02.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, TH, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 201621006638 25 February 2016 (25.02.2016) IN kind of regional protection available): ARIPO (BW, GH, (71) Applicant: ASCENEURON S. A. [CH/CH]; EPFL Innov- GM, ation Park, Batiment B, 1015 Lausanne (CH). TZ, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: QUATTROPANI, Anna; Grand'Rue 5, 1180 DK, Rolle (CH). KULKARNI, Santosh, S.; A206, Temple LV, Trees Apartment, J P Nagar 6th Phase, Bangalore 560078 SM, (IN). GIRI, Awadut Gajendra; Flat no. 408 MB4 Surya GW, KM, ML, MR, NE, SN, TD, TG). City, Chandapura, Bangalore 560099 (IN). TORONTO, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Dawn, V.; 45, rue du bourg, 39230 Saint-Lamain (FR). Published: CROWE, David, Malcolm; Pharmaterials LTD, 5 Boulton — with international search report (Art. 21(3)) Road, Reading Berkshire RG2 ONH (GB). 1-1 IN M iv iv 1-1 IN 1-1 0 \" (54) Title: ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES (57) : The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and in particular as glycosidase inhibitors.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201621006638 | 2016-02-25 | ||
PCT/EP2017/054278 WO2017144637A1 (en) | 2016-02-25 | 2017-02-24 | Acid addition salts of piperazine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807012QA true SG11201807012QA (en) | 2018-09-27 |
Family
ID=58159076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807012QA SG11201807012QA (en) | 2016-02-25 | 2017-02-24 | Acid addition salts of piperazine derivatives |
Country Status (14)
Country | Link |
---|---|
US (3) | US10696668B2 (en) |
EP (1) | EP3419976B1 (en) |
JP (1) | JP6971999B2 (en) |
KR (1) | KR20180132060A (en) |
CN (1) | CN109071526B (en) |
AU (1) | AU2017222962B2 (en) |
BR (1) | BR112018017225A2 (en) |
CA (1) | CA3014572C (en) |
EA (1) | EA201891438A1 (en) |
ES (1) | ES2879351T3 (en) |
MX (1) | MX2018010301A (en) |
SG (1) | SG11201807012QA (en) |
WO (1) | WO2017144637A1 (en) |
ZA (1) | ZA201804870B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6563017B2 (en) | 2014-08-28 | 2019-08-21 | エースニューロン・ソシエテ・アノニム | Glycosidase inhibitor |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
EA201891438A1 (en) * | 2016-02-25 | 2019-01-31 | Асенейрон С. А. | ACID ADDITIVE SALTS DERIVATIVES OF PIPERAZINE |
WO2017144633A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Glycosidase inhibitors |
CN108884078A (en) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | Glycosidase inhibitor |
AU2017378186A1 (en) | 2016-12-16 | 2019-06-13 | Janssen Pharmaceutica Nv | Monocyclic OGA inhibitor compounds |
AU2017400271B2 (en) * | 2017-02-24 | 2020-09-24 | Asceneuron S.A. | Sulfoximine glycosidase inhibitors |
US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
EP3810586A1 (en) * | 2018-06-21 | 2021-04-28 | Janssen Pharmaceutica NV | Oga inhibitor compounds |
WO2020039030A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors |
WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
WO2021094312A1 (en) | 2019-11-11 | 2021-05-20 | Janssen Pharmaceutica Nv | Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds |
WO2021110656A1 (en) | 2019-12-02 | 2021-06-10 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
KR20220118483A (en) | 2019-12-18 | 2022-08-25 | 얀센 파마슈티카 엔.브이. | OGA inhibitor compounds |
WO2021123291A1 (en) | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
JP2023507180A (en) | 2019-12-18 | 2023-02-21 | ヤンセン ファーマシューティカ エヌ.ベー. | OGA inhibitor compounds |
GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
AU2021455177A1 (en) * | 2021-07-05 | 2024-01-18 | Asceneuron Sa | Medicaments comprising glycosidase inhibitors |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1311316A (en) | 1961-04-12 | 1962-12-07 | Science Union Et Compagnie Soc | New piperazine derivatives and their preparations |
NL127996C (en) | 1963-11-19 | |||
US3485757A (en) | 1964-11-23 | 1969-12-23 | Atomic Energy Commission | Thermoelectric composition comprising doped bismuth telluride,silicon and boron |
DE1595923A1 (en) * | 1965-02-20 | 1969-11-27 | Merck Ag E | 1-Aralkyl-4- (thiazolyl-2) -piperazines and processes for their preparation |
GB1165283A (en) | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
US4600025A (en) | 1982-11-18 | 1986-07-15 | Grigg Ronald E | Smoking products comprising nicotine substitutes |
WO1993021181A1 (en) | 1992-04-15 | 1993-10-28 | Merck Sharp & Dohme Limited | Azacyclic compounds |
IL118768A (en) | 1995-07-12 | 2000-10-31 | Akzo Nobel Nv | Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation |
TW504510B (en) | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
US6534496B1 (en) | 1997-04-17 | 2003-03-18 | Takeda Chemical Industries, Inc. | Thermogenic composition and benzazepine thermogenics |
WO1999021850A1 (en) | 1997-10-24 | 1999-05-06 | Neurogen Corporation | 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine d4 receptor subtype ligands |
MXPA03010612A (en) * | 2001-05-22 | 2004-04-02 | Neurogen Corp | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues. |
US6982259B2 (en) | 2002-04-30 | 2006-01-03 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
EP1534703A2 (en) | 2002-06-12 | 2005-06-01 | Abbott Laboratories | Antagonists of melanin concentrating hormone receptor |
JP4881559B2 (en) | 2002-06-27 | 2012-02-22 | ノボ・ノルデイスク・エー/エス | Arylcarbonyl derivatives as therapeutic agents |
DE60330456D1 (en) | 2002-07-05 | 2010-01-21 | Targacept Inc | N-ARYL DIAZASPIROCYCLIC COMPOUNDS, THEIR USE AND THE METHOD FOR THEIR PREPARATION |
KR20050043935A (en) | 2002-09-09 | 2005-05-11 | 얀센 파마슈티카 엔.브이. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
CN1777584A (en) | 2003-04-18 | 2006-05-24 | 伊莱利利公司 | (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht 1f agonists |
JP4552854B2 (en) * | 2003-05-21 | 2010-09-29 | 萬有製薬株式会社 | 2-Aminoquinoline derivative |
DK1723128T3 (en) | 2004-01-06 | 2013-02-18 | Novo Nordisk As | Heteroarlurines and their use as glucokinase activators |
WO2005110982A2 (en) | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
HU227119B1 (en) | 2004-07-29 | 2010-07-28 | Richter Gedeon Nyrt | Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them |
HUP0401522A2 (en) | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation |
US20080287375A1 (en) | 2005-03-01 | 2008-11-20 | Simon Fraser University | Selective Glycosidase Inhibitors, Methods of Making Inhibitors, and Uses Thereof |
TW200724140A (en) | 2005-05-27 | 2007-07-01 | Eisai Co Ltd | Hydantoin compounds |
CA2614518A1 (en) | 2005-07-08 | 2007-01-18 | Novo-Nordisk A/S | Dicycloalkyl urea glucokinase activators |
WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
JP2009532381A (en) | 2006-03-31 | 2009-09-10 | アストラゼネカ アクチボラグ | Bicyclic benzimidazole compounds and use of the compounds as metabotropic glutamate receptor potentiators |
US20090306126A1 (en) | 2006-05-22 | 2009-12-10 | Astrazeneca Ab | Indole Derivatives |
US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
AU2007291870B2 (en) | 2006-08-31 | 2012-12-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
US20100022517A1 (en) | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
WO2008138842A1 (en) | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases |
WO2009011904A1 (en) | 2007-07-19 | 2009-01-22 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
EP2215075B1 (en) | 2007-10-26 | 2013-12-11 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as parp inhibitors |
WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2009127948A1 (en) | 2008-04-17 | 2009-10-22 | Pfizer Inc. | 4- [3- (aryloxy) benzylidene] -3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
EP2276738A1 (en) | 2008-04-17 | 2011-01-26 | Pfizer Inc. | Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
EP2301936A1 (en) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
JP2010065024A (en) | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | Pest control agent containing triazolopyrimidine derivative or salt thereof |
WO2010021381A1 (en) | 2008-08-22 | 2010-02-25 | 武田薬品工業株式会社 | Fused heterocyclic derivative and use thereof |
CA2735269C (en) | 2008-08-29 | 2018-10-16 | Saint Mary's University | Use of gluconacetobacter with reduced use of nitrogen fertilizer to improve beet crop production |
CN102137841B (en) | 2008-09-02 | 2014-05-14 | 日产化学工业株式会社 | Ortho-substituted haloalkylsulfonanilide derivative and herbicide |
TW201030007A (en) | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
EA201171098A1 (en) | 2009-03-02 | 2012-04-30 | Сертрис Фармасьютикалз, Инк. | 8-SUBSTITUTE QUINOLINES AND RELATED ANALOGUES AS SIRTUIN MODULATORS |
WO2010108115A1 (en) | 2009-03-20 | 2010-09-23 | Sanford-Burnham Medical Research Institute | Allosteric jnk inhibitors |
US20120010186A1 (en) | 2009-03-23 | 2012-01-12 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
JP2010270034A (en) | 2009-05-20 | 2010-12-02 | Sumitomo Chemical Co Ltd | Amide compound, and use therefor in controlling plant disease |
WO2010151318A1 (en) | 2009-06-22 | 2010-12-29 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
DE102009049679A1 (en) * | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
US9120781B2 (en) | 2010-05-11 | 2015-09-01 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
US20130196971A1 (en) | 2010-09-17 | 2013-08-01 | Christopher Joseph Aquino | Fatty acid synthase inhibitors |
JP5852666B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
US8933040B2 (en) | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
WO2012061972A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
EP2655388B1 (en) | 2010-12-23 | 2016-06-08 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
TW201300358A (en) | 2011-03-14 | 2013-01-01 | 大正製藥股份有限公司 | Nitrogen-containing condensed heterocyclic compound |
DK2748171T3 (en) | 2011-08-25 | 2016-05-09 | Merck Patent Gmbh | PYRANO [3,2-D] [1,3] THIAZOL AS GLYCOSIDASE INHIBITORS |
WO2013066729A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors |
AR092031A1 (en) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | INHIBITORS OF THE EXTERNAL RENAL MEDULAR POTASSIUM CHANNEL |
EP2882733B1 (en) | 2012-08-08 | 2017-04-26 | Novartis Tiergesundheit AG | Substituted azines as pesticides |
WO2014032187A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
CN105143222B (en) * | 2013-03-14 | 2018-02-02 | 默克专利有限公司 | Glycosidase inhibitor |
CN103435606A (en) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2 and CSK3beta dual inhibitor and application thereof |
SI3318565T1 (en) | 2013-12-05 | 2021-07-30 | Pfizer Inc. | Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides |
EP2913330A1 (en) | 2014-02-27 | 2015-09-02 | Laboratoire Biodim | Condensed derivatives of imidazole useful as pharmaceuticals |
PT3597649T (en) | 2014-04-23 | 2022-01-21 | Dart Neuroscience Llc | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors |
JP6563017B2 (en) | 2014-08-28 | 2019-08-21 | エースニューロン・ソシエテ・アノニム | Glycosidase inhibitor |
MA42293A (en) | 2015-07-02 | 2018-05-09 | Janssen Sciences Ireland Uc | ANTIBACTERIAL COMPOUNDS |
MX2018005342A (en) | 2015-11-02 | 2018-08-15 | Janseen Pharmaceutica Nv | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND. |
WO2017087863A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
ES2893613T3 (en) | 2015-11-25 | 2022-02-09 | Lieber Inst Inc Dba Lieber Inst For Brain Development | Tetrahydro-8H-pyrido[1,2-a]pyrazin-8-ones as COMT inhibitors for the treatment of neurodegenerative disorders |
EP3389658B1 (en) | 2015-12-18 | 2020-11-25 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
WO2017144633A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Glycosidase inhibitors |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
EA201891438A1 (en) * | 2016-02-25 | 2019-01-31 | Асенейрон С. А. | ACID ADDITIVE SALTS DERIVATIVES OF PIPERAZINE |
CN108884078A (en) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | Glycosidase inhibitor |
CA3014376A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Process for the separation of enantiomers of piperazine derivatives |
WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
US11186564B2 (en) | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
AU2017378186A1 (en) | 2016-12-16 | 2019-06-13 | Janssen Pharmaceutica Nv | Monocyclic OGA inhibitor compounds |
CN110312716A (en) | 2016-12-16 | 2019-10-08 | 詹森药业有限公司 | Bicyclic OGA inhibitor compound |
TWI654978B (en) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5-methyl-1,2,4-oxadiazol-3-yl compounds |
EP3577121A1 (en) | 2017-02-06 | 2019-12-11 | Janssen Pharmaceutica NV | Oga inhibitor compounds |
AU2017400271B2 (en) | 2017-02-24 | 2020-09-24 | Asceneuron S.A. | Sulfoximine glycosidase inhibitors |
JP2020509004A (en) | 2017-02-27 | 2020-03-26 | ヤンセン ファーマシューティカ エヌ.ベー. | [1,2,4] -Triazolo [1,5-A] -pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors |
TWI669302B (en) | 2017-05-25 | 2019-08-21 | 美商美國禮來大藥廠 | 5-methyl-1,3,4-oxadiazol-2-yl compounds |
US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
WO2020039027A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Pyrrolidine glycosidase inhibitors |
WO2020039030A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors |
WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
-
2017
- 2017-02-24 EA EA201891438A patent/EA201891438A1/en unknown
- 2017-02-24 KR KR1020187027133A patent/KR20180132060A/en not_active Application Discontinuation
- 2017-02-24 SG SG11201807012QA patent/SG11201807012QA/en unknown
- 2017-02-24 CA CA3014572A patent/CA3014572C/en active Active
- 2017-02-24 EP EP17707011.7A patent/EP3419976B1/en active Active
- 2017-02-24 ES ES17707011T patent/ES2879351T3/en active Active
- 2017-02-24 JP JP2018544534A patent/JP6971999B2/en active Active
- 2017-02-24 AU AU2017222962A patent/AU2017222962B2/en active Active
- 2017-02-24 US US16/079,162 patent/US10696668B2/en active Active
- 2017-02-24 WO PCT/EP2017/054278 patent/WO2017144637A1/en active Application Filing
- 2017-02-24 CN CN201780013496.8A patent/CN109071526B/en active Active
- 2017-02-24 BR BR112018017225A patent/BR112018017225A2/en active Search and Examination
- 2017-02-24 MX MX2018010301A patent/MX2018010301A/en unknown
-
2018
- 2018-07-19 ZA ZA2018/04870A patent/ZA201804870B/en unknown
-
2020
- 2020-05-18 US US16/877,284 patent/US11591327B2/en active Active
-
2022
- 2022-12-06 US US18/062,295 patent/US20230120169A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200385375A1 (en) | 2020-12-10 |
MX2018010301A (en) | 2019-05-20 |
US20230120169A1 (en) | 2023-04-20 |
JP2019506429A (en) | 2019-03-07 |
AU2017222962B2 (en) | 2021-03-25 |
CA3014572C (en) | 2023-10-03 |
WO2017144637A1 (en) | 2017-08-31 |
AU2017222962A1 (en) | 2018-08-23 |
EA201891438A1 (en) | 2019-01-31 |
CN109071526A (en) | 2018-12-21 |
CN109071526B (en) | 2023-02-28 |
KR20180132060A (en) | 2018-12-11 |
JP6971999B2 (en) | 2021-11-24 |
EP3419976B1 (en) | 2021-04-07 |
US10696668B2 (en) | 2020-06-30 |
US20190055233A1 (en) | 2019-02-21 |
ES2879351T3 (en) | 2021-11-22 |
BR112018017225A2 (en) | 2019-01-15 |
EP3419976A1 (en) | 2019-01-02 |
CA3014572A1 (en) | 2017-08-31 |
US11591327B2 (en) | 2023-02-28 |
ZA201804870B (en) | 2023-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807012QA (en) | Acid addition salts of piperazine derivatives | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201901445TA (en) | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201804934PA (en) | Novel Compounds | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201807005VA (en) | Process for the separation of enantiomers of piperazine derivatives | |
SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
SG11201903230QA (en) | TCRa HOMING ENDONUCLEASE VARIANTS | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201805170XA (en) | Cellular glycosaminoglycan compositions and methods of making and using | |
SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
SG11201908091QA (en) | Aqueous anti-pd-l1 antibody formulation | |
SG11201901477PA (en) | Compound for use in the treatment of neurogenic orthostatic hypotension | |
SG11201408171SA (en) | Fbxo3 inhibitors |